Lipisafe CV 10mg/75mg Capsule is a combination medication containing Atorvastatin 10mg and Clopidogrel 75mg, indicated for the management of cardiovascular risk in patients with a history of atherosclerotic cardiovascular disease or those at high risk of thrombotic events. Atorvastatin, a statin class drug, functions by inhibiting HMG-CoA reductase, thereby reducing cholesterol synthesis in the liver, leading to decreased levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Clopidogrel, an antiplatelet agent, irreversibly inhibits the P2Y12 component of ADP receptors on platelet surfaces, preventing platelet aggregation and reducing the risk of thrombus formation. The combined action of Lipisafe CV addresses both lipid abnormalities and platelet aggregation, offering comprehensive cardiovascular protection. This medication is typically prescribed for secondary prevention of myocardial infarction, stroke, and other vascular events in patients with established coronary artery disease, peripheral arterial disease, or cerebrovascular disease. It should be used under medical supervision, with regular monitoring of lipid profiles, liver function tests, and assessment for any bleeding complications. Patients should be advised on adherence, potential side effects, and to report any unusual bleeding or muscle pain promptly.